Stockreport

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

Cel-Sci Corporation  (CVM) 
NASDAQ:AMEX Investor Relations: cel-sci.com/investor_relations.html
PDF Biomarker used to select patients who are more likely have favorable outcomes, supporting a successful confirmatory Registration StudyPatients with low PD-L1 expression [Read more]